Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedrine proposed rule 150-day comment period extension urged by supplement coalition.

This article was originally published in The Tan Sheet

Executive Summary

EPHEDRINE FDA GUIDANCE DOCUMENT IN LIEU OF RULEMAKING urged by the Dietary Supplement Safety and Science Coalition in Dec. 1 comments to the agency. Responding to FDA's proposed rule on ephedrine alkaloids in dietary supplements, the Denver, Colo.-based industry group "strongly recommends that the FDA terminate its rulemaking...and, instead, develop and issue a guidance document which incorporates the suggestions of the DSSSC." FDA's June 4 proposed rule would, among other things, limit ephedrine single-dose amounts to 8 mg ("The Tan Sheet" June 9, pp. 20-25). The comment period for the proposal ended Dec. 2.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087843

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel